DIA Survey Results on AI Adoption in Drug Development

Mary Jo Lamberti

Mary Jo Lamberti, PhD is a Research Associate Professor at Tufts University School of Medicine and the Director of Sponsored Research at Tufts CSDD. She has extensive experience benchmarking drug development operating practices. Her research focuses on a variety of areas including patient recruitment and retention in clinical trials, clinical research workforce issues, outsourcing and partnerships, and investigative site initiation and management. In addition, she has examined the impact of technologies and digital solutions in clinical trials. Dr. Lamberti has been a frequent speaker at global industry conferences and has published extensively. She holds a B.A. from Wellesley College and a Ph.D. from Boston University.

Abstract: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) collaborated on a research study with a working group of 16 biopharmaceutical and contract research organizations examining the current use of artificial intelligence and machine learning to support the continuum of drug development with a focus on clinical operations and development. The global survey findings will be discussed in detail in this presentation and participants will gain insight into the level of adoption of artificial intelligence across biopharmaceutical companies and CROs and learn about the top activities where AI/ML is being implemented and utilized. Participants will also learn about the effectiveness of the impact of AI/ ML including time savings, cost, and deployment of organizational resources. Last, the challenges to the implementation of AI/ML will be discussed as well as the opportunities for the pharmaceutical industry.